Springworks Therapeutics (SWTX) reported preliminary Q4 net product revenue Monday of $61.5 million.
Analysts polled by FactSet expect $54.6 million.
For all of 2024, the company expects preliminary net product revenue of $172 million.
Analysts polled by FactSet expect $186.4 million.
The company added its preliminary cash, cash equivalents and marketable securities totaled $461.9 million as of Dec. 31, enough to 'fund operations through profitability,' which the company expects achieving in the first half of 2026.
Springworks' shares fell 9% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.